Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
AstraZeneca |
---|---|
Information provided by: | AstraZeneca |
ClinicalTrials.gov Identifier: | NCT00351910 |
To evaluate the efficacy of quetiapine fumarate sustained release (Seroquel SR™) in combination with an antidepressant versus an antidepressant alone in patients with Major Depressive Disorder.
PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.
Condition | Intervention | Phase |
---|---|---|
Major Depressive Disorder |
Drug: Quetiapine Drug: Amitriptyline Drug: Bupropion Drug: Citalopram Drug: Duloxetine Drug: Escitalopram Drug: Fluoxetine Drug: Paroxetine Drug: Sertraline Drug: Venlafaxine |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study |
Official Title: | A Multi-Centre, Double-Blind, Randomised, Parallel-Group, Placebo-Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SRTM) in Combination With an Antidepressant in the Treatment of Patients With Major Depressive Disorder With Inadequate Response to an Antidepressant Treatment |
Enrollment: | 494 |
Study Start Date: | September 2005 |
Study Completion Date: | April 2007 |
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study Director: | Seroquel Medical Science Director, MD | AstraZeneca |
Study ID Numbers: | D1448C00007, ONYX, EUDRACT No: 2005-0055053-22 |
Study First Received: | July 12, 2006 |
Last Updated: | December 18, 2008 |
ClinicalTrials.gov Identifier: | NCT00351910 |
Health Authority: | Belgium: Directorate general for the protection of Public health: Medicines; Australia: Department of Health and Ageing Therapeutic Goods Administration; Czech Republic: State Institute for Drug Control; Finland: National Agency for Medicines; France: Afssaps - French Health Products Safety Agency; Germany: Federal Institute for Drugs and Medical Devices; Norway: Norwegian Medicines Agency; Poland: Ministry of Health; South Africa: Medicines Control Council; Sweden: Medical Products Agency |
Major Depressive Disorder MDD |
Depression Depressive Disorder, Major Depressive Disorder Citalopram Paroxetine Serotonin Duloxetine Behavioral Symptoms Fluoxetine |
Quetiapine Dopamine Mental Disorders Venlafaxine Bupropion Mood Disorders Amitriptyline Sertraline Dexetimide |
Dopamine Uptake Inhibitors Neurotransmitter Agents Neurotransmitter Uptake Inhibitors Adrenergic Agents Molecular Mechanisms of Pharmacological Action Adrenergic Uptake Inhibitors Physiological Effects of Drugs Psychotropic Drugs Pathologic Processes Sensory System Agents Therapeutic Uses Analgesics Antidepressive Agents, Second-Generation |
Antidepressive Agents Disease Tranquilizing Agents Central Nervous System Depressants Antipsychotic Agents Serotonin Uptake Inhibitors Pharmacologic Actions Antidepressive Agents, Tricyclic Serotonin Agents Analgesics, Non-Narcotic Dopamine Agents Peripheral Nervous System Agents Central Nervous System Agents |